NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Thursday reported second-quarter earnings of $938 million. The North Chicago, Illinois-based company said it had net income ...

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

AbbVie has reported topline outcomes from the first of two trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib).

AbbVie Inc. (NYSE: ABBV) is reportedly negotiating the acquisition of Gilgamesh Pharmaceuticals, a privately held mental ...

This was the stock's third consecutive day of losses.

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people ...

According to the update, the $823 million expense is related to acquired IPR&D, typically incurred through collaborations, ...

Shares of AbbVie Inc. ABBV dropped 0.43% to $170.35 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.02% to 5,985.38 ...